PharVision Advisers’s Envista NVST Stock Holding History

PharVision Advisers’s Portfolio NVST Stock Details NVST Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-15,070	Closed	-$307K	–	908
2025 Q3	$307K	Buy	+15,070	New	+$310K	0.17%	214

Other funds holding NVST

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Ariel Investments Chicago, Illinois $8.93B AUM 29.58% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

GCM

Gates Capital Management New York $3.66B AUM 12.63% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

PharVision Advisers's NVST Position: Q4 2025 in Review

PharVision Advisers sold out of Envista (NVST) in Q4 2025, closing a stake of 15,070 shares — an estimated $307K sold.

PharVision Advisers first reported a position in NVST in Q3 2025 and held it in 1 quarter. The position peaked at $307K in Q3 2025. 336 funds tracked by Wall St. Rank hold NVST as of Q4 2025.

PharVision Advisers reported no remaining Envista position as of Q4 2025 after selling out during the quarter.
PharVision Advisers sold 15,070 Envista shares in Q4 2025, an estimated $307K.
PharVision Advisers first reported a position in Envista in Q3 2025 and held it in 1 quarter.
PharVision Advisers's Envista position peaked at $307K in Q3 2025.
336 funds tracked by Wall St. Rank held Envista as of Q4 2025.

Based on PharVision Advisers's 13F filing for Q4 2025, filed 17 Feb 2026.